FunPep Advances Two Drug Development

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 20, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

FunPep Advances Two Drug Development Projects; Secures Funding Through Rights Issue

Source disclosure: February 20, 2026 FunPep Company Limited [4881.T] TOKYO, Feb 20 (Pulse News Wire) – FunPep Company Limited (4881.T) reported progress on its two key drug development projects targeting allergic rhinitis and skin ulcers. FPP004X, aimed at alleviating symptoms of allergic rhinitis, completed patient dosing in October 2025 and expects results in Q2 2026. SR379, designed to promote wound healing and combat infections in skin ulcers, began additional Phase III trials i